In millions of CNY, except per share items | Sep-30-22 | Sep-30-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 | Sep-30-16 | Sep-30-15 |
| 20-F | 20-F | 20-F | S-1/A | 20-F | 20-F | 20-F | 20-F |
Revenues: |
Agri-biotech and product development | | | | | | | | 3.6 |
Production and distribution of hybrid seeds | | | | | | | | 376.3 |
Total revenues | 52.6 | 46.4 | 52.5 | 92.4 | 12.9 | 0.9 | 0.5 | 376.6 |
Revenue growth [+] | 13.3% | -11.6% | -43.2% | 615.1% | 1385.9% | 80.9% | -99.9% | -9.3% |
Agri-biotech and product development | | | | | | | | 0.7% |
Production and distribution of hybrid seeds | | | | | | | | -9.3% |
Cost of goods sold | 36.4 | 33.6 | 49.0 | 105.3 | 7.0 | 0.7 | 0.0 | 264.0 |
Gross profit | 16.2 | 12.8 | 3.5 | -12.8 | 5.9 | 0.2 | 0.5 | 112.5 |
Gross margin | 30.8% | 27.6% | 6.7% | -13.9% | 45.5% | 22.1% | 100.0% | 29.9% |
Selling, general and administrative [+] | 21.7 | 78.9 | 62.9 | 31.3 | 32.6 | 36.1 | 33.0 | 80.7 |
Sales and marketing | 7.3 | 5.6 | 4.8 | 4.0 | 0.4 | | | 40.0 |
General and administrative | 14.3 | 73.3 | 58.1 | 27.2 | 32.1 | 36.1 | 33.0 | 40.7 |
Research and development | 7.4 | 2.0 | 4.1 | 13.3 | 27.1 | 38.7 | 41.3 | 48.7 |
Other operating expenses | | 69.9 | 28.1 | 4.1 | -12.7 | -5.0 | -24.1 | -18.2 |
EBITDA [+] | -9.0 | -129.6 | -81.0 | -47.7 | -24.7 | -41.9 | -18.5 | 31.9 |
EBITDA growth | -93.1% | 60.1% | 69.8% | 93.5% | -41.1% | 126.6% | -157.9% | 688.3% |
EBITDA margin | -17.1% | -279.2% | -154.2% | -51.6% | -190.7% | -4812.5% | -3841.0% | 8.5% |
Depreciation | 3.1 | 7.5 | 9.8 | 10.9 | 10.5 | 21.5 | 24.6 | 22.9 |
EBITA | -12.1 | -137.1 | -90.8 | -58.6 | -35.2 | -63.4 | -43.1 | 9.0 |
EBITA margin | -23.0% | -295.4% | -172.8% | -63.4% | -272.0% | -7287.7% | -8952.2% | 2.4% |
Amortization of intangibles | 0.8 | 0.8 | 0.8 | 2.9 | 5.9 | 6.2 | 6.6 | 7.7 |
EBIT [+] | -12.9 | -137.9 | -91.6 | -61.5 | -41.1 | -69.6 | -49.7 | 1.3 |
EBIT growth | -90.6% | 50.6% | 48.9% | 49.6% | -40.9% | 40.0% | -3808.7% | -105.5% |
EBIT margin | -24.5% | -297.1% | -174.4% | -66.5% | -318.0% | -7994.9% | -10332.0% | 0.4% |
Interest expense, net [+] | 8.2 | 8.6 | 5.8 | 4.7 | 22.8 | 7.6 | 7.5 | 18.6 |
Interest expense | 8.2 | 8.6 | 5.8 | 4.7 | 22.8 | 9.0 | 7.6 | 18.6 |
Interest income | | | | | | 1.4 | 0.1 | |
Other income (expense), net [+] | 23.4 | 19.6 | -5.0 | 1.0 | -88.9 | -44.7 | -8.3 | 0.8 |
Impairment of equity method investments | -2.9 | -6.0 | -6.0 | | -2.4 | | | |
Asset impairment charges | | -69.9 | -28.1 | -4.1 | -1.4 | -44.7 | | |
Gain (loss) on sale of business | | | | | -90.7 | | | |
Other | 15.7 | 14.9 | -6.7 | -3.6 | | | -8.3 | -18.2 |
Pre-tax income | 2.3 | -126.9 | -102.4 | -65.1 | -152.8 | -121.8 | -65.5 | -16.5 |
Income taxes | 0.0 | 0.2 | 0.4 | 0.5 | 0.9 | 0.0 | 0.0 | 0.0 |
Tax rate | | | | | | 0.0% | 0.0% | 0.0% |
Minority interest | 8.6 | -35.6 | -17.6 | -3.5 | 0.9 | -30.6 | -11.3 | -4.0 |
Earnings from continuing ops | -6.3 | -91.5 | -85.3 | -62.1 | -153.7 | -213.1 | -61.8 | -13.8 |
Earnings from discontinued ops | | | | | | 15.6 | -3.8 | |
Net income | -6.3 | -91.5 | -85.3 | -62.1 | -153.7 | -197.5 | -65.6 | -13.8 |
Net margin | -11.9% | -197.2% | -162.4% | -67.2% | -1188.7% | -22702.9% | -13633.7% | -3.7% |
|
Basic EPS [+] | ($1.09) | ($16.29) | ($16.95) | ($14.85) | ($50.18) | ($75.88) | ($22.39) | ($0.61) |
Growth | -93.3% | -3.9% | 14.2% | -70.4% | -33.9% | 239.0% | 3595.7% | 44.6% |
Diluted EPS [+] | ($1.09) | ($16.29) | ($16.95) | ($14.85) | ($50.18) | ($75.88) | ($22.39) | ($0.61) |
Growth | -93.3% | -3.9% | 14.2% | -70.4% | -33.9% | 239.0% | 3595.7% | 44.6% |
|
Dividends per share | $0.42 | | | | | | | |
|
Shares outstanding (basic) [+] | 5.8 | 5.6 | 5.0 | 4.2 | 3.1 | 2.8 | 2.8 | 22.8 |
Growth | 2.8% | 11.7% | 20.2% | 36.6% | 9.0% | 1.8% | -87.9% | 0.2% |
Shares outstanding (diluted) [+] | 5.8 | 5.6 | 5.0 | 4.2 | 3.1 | 2.8 | 2.8 | 22.8 |
Growth | 2.8% | 11.7% | 20.2% | 36.6% | 9.0% | 1.8% | -87.9% | 0.2% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |